What Behringwerke AG does

Behringwerke AG, operating commercially as CSL Behring GmbH, is a German biopharmaceutical company headquartered in Marburg, Hesse, that develops, manufactures, and markets plasma-derived and recombinant biotherapeutics for rare and serious diseases. The entity traces its origin to 1904, when Nobel laureate Emil von Behring founded the Behringwerke in Marburg for serum and vaccine production; it is now a wholly-owned subsidiary of CSL Limited (ASX:CSL), an Australian specialty biopharmaceutical group. CSL Behring employs more than 3,300 people at the Marburg site alone, within the broader Behringwerke Industrial Park that hosts over 6,500 workers across GSK Vaccines, Siemens Healthineers, BioNTech, and CSL. Therapeutic areas covered include hemophilia A and B, von Willebrand disease, primary and secondary immunodeficiencies, autoimmune disease, hereditary angioedema, alpha-1 antitrypsin deficiency, Rh incompatibility prophylaxis, and critical-care bleeding management.

Core capabilities center on plasma protein biotechnology and recombinant DNA technology, including proprietary plasma fractionation and AAV-based gene therapy. Manufacturing is anchored by a $470 million plasma fractionation facility (opened March 2022) and the 40,000 square meter R&D Campus M600, which houses CSL Innovation GmbH — the R&D subsidiary with 500+ employees and approximately 800 square meters of laboratory space reserved for external start-ups and academic partners. The flagship innovation is HEMGENIX (etranacogene dezaparvovec), an AAV-based gene therapy that delivers a functional copy of the Factor IX gene to liver cells, enabling long-term endogenous factor production in adults with severe and moderately severe hemophilia B. HEMGENIX received European Commission conditional marketing authorization in February 2023 — the first gene therapy approved in Europe for hemophilia B — and was launched commercially in Germany following reimbursement agreements with statutory and private health insurers. The product was developed by uniQure and licensed to CSL via a 2021 commercialization agreement.

The business model is enterprise biopharmaceutical sales: products are prescribed by specialty healthcare providers (hematologists, immunologists, hemophilia treatment centers) and reimbursed through national health insurance systems across 100+ countries. The company operates a vertically integrated supply chain including 15 plasma donation centers throughout Germany and field sales forces targeting hospitals, specialty clinics, and rare disease treatment centers. Revenue for CSL Behring GmbH specifically is not separately disclosed; parent CSL Limited reported FY2023 net profit of USD 2.61 billion (20% growth at constant currency, with 31% revenue growth) and FY2025 net profit of USD 3.3 billion (14% growth). Beyond its products, the company maintains a regional innovation-ecosystem role through partnerships with Philipps University Marburg, IBiNa, Pharmaserv/Infrareal Holding, the City of Marburg, and various start-up programs.

Name

Behringwerke AG

Legal name

CSL Behring GmbH

Website

https://cslbehring.de

Company type

Private

Founded year

1904

Operating status

Operating

Headcount range

11–50 employees

Short description

Behringwerke AG (operating as CSL Behring GmbH) is a German biopharmaceutical subsidiary of CSL Limited that develops and manufactures plasma-derived and recombinant biotherapeutics — including the HEMGENIX gene therapy for hemophilia B — for patients with rare and serious diseases across more than 100 countries.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals (Plasma-derived and Gene Therapy)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industries

Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)

Keywords

• Plasma-derived biotherapeutics
• Immunoglobulin therapies
• Coagulation factor therapies
• Hemophilia B gene therapy
• Rare disease biopharmaceuticals

Headquarters

HQ city

Marburg

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Biopharmaceutical Product Sales: CSL Behring generates revenue primarily through the sale of plasma-derived and recombinant biopharmaceutical products for rare and serious diseases. Revenue increased 31% at constant currency in FY2023. The company reported $2.61 billion net profit in FY2023 with 20% profit growth, and $3.3 billion net profit in FY2025 with 14% profit growth.
2. Gene Therapy (HEMGENIX): HEMGENIX received EU approval in 2023 and is now available in Germany for adults with severe and moderately severe hemophilia B. The therapy is covered by statutory and private health insurance following reimbursement agreement with German health insurers, representing a new revenue stream with outcome-based reimbursement models.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

CSL Behring develops, manufactures and markets plasma-derived and recombinant biotherapeutics for patients with rare and serious diseases, including immunoglobulins, coagulation factors, albumin, and AAV-based gene therapy. Its flagship product HEMGENIX is the first gene therapy approved in Europe for hemophilia B (adults with severe and moderately severe disease), administered as a single infusion that delivers functional Factor IX genetic instructions to liver cells for endogenous factor production. The Marburg site handles manufacturing under strictly controlled conditions and operates a $470 million plasma fractionation facility.

Product overview

CSL Behring (Behringwerke AG) develops, manufactures, and markets a comprehensive portfolio of biotherapeutics for rare and serious diseases. The product range includes plasma-derived therapies (immunoglobulins, coagulation factors, albumin) and recombinant products (gene therapies, recombinant proteins). Key therapeutic areas include hemophilia, immunodeficiencies, hereditary angioedema, alpha-1 antitrypsin deficiency, and Rh incompatibility prophylaxis. The flagship innovation is HEMGENIX®, the first approved gene therapy for hemophilia B.

Differentiator

Problem solved

Functional benefit

Products and services

• HEMGENIX (etranacogene dezaparvovec) A one-time AAV5-based gene therapy for adults with severe and moderately severe hemophilia B that delivers a functional copy of the Factor IX gene to liver cells, enabling long-term endogenous production of the clotting factor. Administered at specialized hemophilia treatment centers under reimbursement agreements with German statutory (GKV) and private (PKV) health insurers.
• Plasma-derived Biotherapeutics (immunoglobulins, coagulation factors, albumin) Plasma-derived biotherapeutics including immunoglobulins, coagulation factors, and albumin products for treatment of bleeding disorders, immunodeficiencies, and other rare diseases. Manufactured from plasma collected across CSL's 15 German donation centers and processed in the $470 million Marburg fractionation facility.
• Immunoglobulin Therapies Plasma protein therapies for primary and secondary immunodeficiencies and autoimmune diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP). Provides antibody replacement for patients with compromised immune systems.
• Coagulation Factor Therapies Clotting factor replacement therapies for congenital and acquired bleeding disorders including hemophilia A, hemophilia B, and von Willebrand disease. Used for prophylaxis, on-demand treatment, and surgical bleeding management.
• Hereditary Angioedema (HAE) Treatments Specialized therapies for prevention and treatment of hereditary angioedema attacks, a rare genetic condition causing potentially life-threatening swelling episodes affecting the airways, abdomen, and extremities.
• Alpha-1 Antitrypsin Deficiency (AATD) Therapies Augmentation therapies for alpha-1 antitrypsin deficiency, a genetic condition causing early-onset emphysema and potential liver disease. Used to slow progression of lung destruction in affected patients.
• Rh Incompatibility Prophylaxis Products for prevention of Rh incompatibility during pregnancy to protect against hemolytic disease of the fetus and newborn. Anti-D prophylaxis administered to Rh-negative pregnant women at risk of Rh incompatibility.
• Recombinant Products Recombinantly manufactured biotherapeutics developed through genetic engineering technologies, complementing the plasma-derived portfolio with non-plasma-derived alternatives for selected indications.
• Beriglobin (Human Normal Immunoglobulin) Human normal immunoglobulin for passive immunization, available as an injection solution in ready-to-use syringes for convenient administration.

Quantifiable outcome

• 14% profit growth in FY2025 with $3.3 billion net profit
• +4 more outcomes

Named customers5 records

Segments7 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Pharmaserv / Infrareal HoldingcoreStrategic or Co-development Partner · 1 January 2024Pharmaserv operates the Behringwerke Industrial Park. CSL collaborates on developing an innovation hub with approximately 11,500 square meters at the Berghof site in Marbach, where start-ups and biotech companies can rent flexible laboratory spaces. Managing Director Dr. Martin Egger represents both Pharmaserv and Infrareal Holding in joint initiatives.
• Philipps University MarburgcoreStrategic or Co-development Partner · 1 January 2023CSL collaborates with Philipps University Marburg on research, talent development, and innovation transfer. Joint initiatives include the new master's program in molecular biotechnology (accredited 2023), lung research collaboration on COPD treatments, and joint RNA molecule research for immune cycle disorders. University President Prof. Dr. Thomas Nauss participates in joint marketing efforts for Marburg as a biotech location.
• City of MarburgcoreStrategic or Co-development PartnerLord Mayor Dr. Thomas Spies leads joint efforts with CSL to strengthen Marburg as a research and production location. Collaborations include overall marketing strategy for the Marburg location, joint appearance at Expo Real trade fair, and development of innovation ecosystem including Tiny Festival and cross-mentoring programs.
• IBiNa (Biotechnology and Nanotechnology Initiative)coreStrategic or Co-development PartnerIBiNa brings together Philipps University Marburg, biotech companies, and the university town of Marburg. Dr. Lars Grönke and Dr. Lutz Bonacker serve as board members. The initiative aims to sustainably promote biotechnology and nanotechnology development potential in the region through events like 'IBiNa on site' hosted at CSL's M600 campus.
• Provadis (Partner for Education and Consulting)coreImplementation/ SI/ Consulting PartnerProvadis partners with CSL Behring on the Re-Start and Re-StartPlus programs, providing educational and consulting services for training refugees and other disadvantaged individuals for apprenticeships as chemical production specialists at the Marburg site.
• ZFC (Center for Chemistry e.V.)minorStrategic or Co-development PartnerCSL Innovation hosts the Inventors' Lab, organized by ZFC as part of the 'Schule 3.0 - MINT for Future' initiative. The program provides MINT (STEM) students hands-on research and development experience at CSL's facilities.
• uniQurecoreTechnology or IntegrationCSL closed a commercialization and license agreement with uniQure for hemophilia B gene therapy (etranacogene dezaparvovec/HEMGENIX) in May 2021. The therapy was developed by uniQure and CSL acquired global rights to commercialize the investigational AAV-based gene therapy.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Sanofi: Global biopharmaceutical incumbent with a deep rare-disease franchise (Genzyme legacy) spanning enzyme replacement, hemophilia products (Eloctate, Altuviiio), and immunology. Overlaps with CSL Behring in HAE and other rare conditions.
• Roche: Swiss global pharma major with significant hemophilia franchise (Hemlibra) and diagnostics business. Competes with CSL Behring in coagulation through long-acting recombinant factors and with gene therapy players via partner Spark Therapeutics.
• Takeda Pharmaceutical: Japanese global pharma major that acquired Shire's rare disease franchise (incl. hemophilia). Competes with CSL Behring in coagulation disorders and rare diseases as part of a much broader specialty and rare-disease portfolio.
• Pfizer: US global pharma giant with established rare hematology, immunology, and gene therapy interests. Competes with CSL Behring across multiple rare-disease segments as part of its diversified biopharma portfolio.

Emerging players

• BioMarin Pharmaceutical: US rare-disease biotech whose Roctavian is the first approved hemophilia A gene therapy. Directly competes with CSL Behring's HEMGENIX in the curative gene therapy space for hemophilia patients.
• uniQure: Dutch gene therapy developer that originally developed etranacogene dezaparvovec (HEMGENIX) and licensed global rights to CSL. Strategic technology partner and a comparable AAV-platform rare-disease player.

Regional players

• Bayer: German-headquartered pharma major with substantial life-sciences operations in Germany and a rare-disease portfolio touching hemophilia and immunology. Comparable as a German-rooted incumbent with overlapping therapeutic areas.

Direct peers

• Grifols: Spanish global plasma-derived therapeutics leader producing immunoglobulins, clotting factors, and albumin. Direct competitor to CSL Behring across the same plasma fractionation portfolio and therapeutic areas, with its own plasma donation network.
• Octapharma: Swiss family-owned plasma products manufacturer with strong franchises in coagulation disorders, immunoglobulins, and critical care. Competes head-to-head with CSL Behring in hemophilia and IVIG across European and global markets.
• Kedrion: Italian plasma-derived biopharmaceutical company producing coagulation factors, immunoglobulins, and albumin. Direct competitor in rare disease and bleeding disorder treatments with overlapping European commercial footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/CSLBehringDE
• LinkedInlinkedin.com/company/behringwerke-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Behringwerke AG